Vanguard Capital Management’s Spero Therapeutics SPRO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$2.46M Hold
2,036,226
– – ﹤0.01% 3314
2026
Q2
$4.5M Buy
2,036,226
+236,346
+13% +$618K ﹤0.01% 3160
2026
Q1
$4.21M Buy
+1,799,880
New +$4.27M ﹤0.01% 3126

Other funds holding SPRO

Vanguard Capital Management's SPRO Position: Q3 2026 in Review

Vanguard Capital Management held its Spero Therapeutics (SPRO) position steady in Q3 2026 at 2,036,226 shares worth $2.46M. The position accounts for ﹤0.01% of the portfolio, ranked #3314.

Vanguard Capital Management first reported a position in SPRO in Q1 2026 and has held it in 3 quarters since. The position peaked at $4.5M in Q2 2026. 44 funds tracked by Wall St. Rank hold SPRO as of Q3 2026.

  • Vanguard Capital Management held 2,036,226 shares of Spero Therapeutics worth $2.46M as of Q3 2026.
  • Vanguard Capital Management left its Spero Therapeutics share count unchanged in Q3 2026.
  • Spero Therapeutics made up ﹤0.01% of Vanguard Capital Management's portfolio in Q3 2026, its #3314 holding.
  • Vanguard Capital Management first reported a position in Spero Therapeutics in Q1 2026 and has held it in 3 quarters since.
  • Vanguard Capital Management's Spero Therapeutics position peaked at $4.5M in Q2 2026.
  • 44 funds tracked by Wall St. Rank held Spero Therapeutics as of Q3 2026.

Based on Vanguard Capital Management's 13F filing for Q3 2026, filed 13 Nov 2026.